

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Diabetes risk after COVID-19, angiotensin receptor blockers for COVID-19 treatment, bivalent vaccines

Peer reviewed journals featured:

- A systematic review on risk for newly diagnosed diabetes after COVID-19 [here](#)
- A randomised controlled trial of angiotensin receptor blockers for COVID-19 treatment [here](#)
- A narrative review on a 'VaxTax' model for a global vaccine pandemic response [here](#)
- Observational studies on:
 - Bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection [here](#)
 - Paxlovid associated with decreased hospitalisation rate in US COVID-19 adults [here](#)
 - Herpes zoster risk among recipients of COVID-19 vaccine [here](#)
 - Wild-type COVID-19 vaccine cross-neutralisation of BA.4/5/2.75 subvariants in BA.2 breakthrough infections [here](#)
 - Four vaccine doses or hybrid immunity in patients on immunosuppressive therapies [here](#)
 - In-hospital and 6-month outcomes in COVID-19 patients supported with ECMO [here](#)
 - Safety of the fourth Comirnaty (Pfizer) vaccine [here](#) and associated commentary [here](#)
 - Vaccine effectiveness against reinfection during Alpha, Delta, or Omicron waves [here](#)
 - Effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 [here](#)
 - Meta-summaries for awareness and understanding of COVID-19 vaccine safety [here](#)
 - Vitamin D status and severity of COVID-19 [here](#)
 - Thrombosis and thrombocytopenia after COVID-19 vaccination in the UK [here](#)
- Commentary on:
 - COVID-19 waves in Canada [here](#)
 - Understanding and neutralising COVID-19 misinformation and disinformation [here](#)
 - Surveillance of COVID-19 effects and future emerging infections in pregnancy [here](#)

Letters and correspondence discussed:

- Vaccination status among parents of hospitalised children during Delta and Omicron waves [here](#)
- COVID-19 and excess all-cause mortality in the US and 20 comparison countries [here](#)
- Omicron sublineage BQ.1.1 resistance to monoclonal antibodies [here](#)
- Mucosal IgA against Omicron infection [here](#)
- Neutralisation of Omicron subvariant BA.2.75 after bivalent vaccination [here](#)

Pre-peer review articles featured:

- Incidence, characteristics, risk factors, and outcomes of diabetic ketoacidosis in COVID-19 patients without prior insulin dependence and compared with influenza [here](#)
- Improved neutralisation of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent BA.4/5 vaccine [here](#)
- Characterising post-COVID syndrome in outpatient and inpatient setting in Sweden [here](#)
- Viral and symptom rebound differences between paxlovid and untreated COVID-19 people [here](#)
- Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralising antibodies [here](#)
- Efficacy of the wild-type/Omicron BA.1 bivalent vaccine as the second booster dose against Omicron BA.2 and BA.5 [here](#)
- Factors associated with relief of long COVID symptoms at 12-months [here](#)
- AI based simulation for predicting future high-risk SARS-CoV-2 variants [here](#)
- Neutralising antibodies to Omicron after fourth vaccine dose in immunocompromised patients [here](#)
- Changes in US population immunity against infection and severe disease from Omicron [here](#)
- Circulating monocytes and monocyte activation in pulmonary long COVID [here](#)
- Comparative aerosol and surface stability of SARS-CoV-2 variants of concern [here](#)

Guidance and reports

- The World Health Organization published its weekly epidemiological report on COVID-19 [here](#)
- The National Clinical Evidence Taskforce released updated recommendations and flowcharts [here](#)
- The BMJ updated its best practice guides on COVID-19 [here](#)

News and blogs

- How immune-evasive Omicron offspring and a lack of mitigation measures could shape a COVID-19 winter wave in the US [here](#)
- “Grotesque inequity” that only a quarter of paxlovid courses go to poorer countries [here](#)
- UK tracking of COVID-19 [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).